|

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

RECRUITINGPhase 1Sponsored by iCell Gene Therapeutics
Actively Recruiting
PhasePhase 1
SponsoriCell Gene Therapeutics
Started2019-07-01
Est. completion2026-07
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04162353

Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Signed written informed consent; Patients volunteer to participate in the research
* Diagnosis is mainly based on the World Health Organization (WHO) 2008
* Patients have exhausted standard therapeutic options
* Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks
* Female must be not pregnant during the study

Exclusion Criteria:

* Patients declining to consent for treatment
* Prior solid organ transplantation
* Potentially curative therapy including chemotherapy or hematopoietic cell transplant
* Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents

Conditions4

CancerMultiple Myeloma in RelapsePlasmacytoid; LymphomaRefractory Multiple Myeloma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.